The MATTERHORN study is a randomized, double-blind, placebo-controlled phase III study to explore the therapeutic effects of preoperative FLOT plus the novel anti-PD-L1 antibody durvalumab in resectable gastric cancer and esophagogastric junction cancer. Here, CD274 is linked to gastric cancer.